Evidence map›Paper›PMID 9021173›Full record

Trial reportAntimicrobial agents and chemotherapy1997

Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract.

C P Kelly, S Chetham, S Keates, E F Bostwick, A M Roush, I Castagliuolo, J T LaMont, C Pothoulakis

Open access · bronzeAbstract readClinical TrialClinical Trial, Phase I
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. TargetingFrontiers in microbiology · 2018
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

C P KellyEvans Memorial Department of Clinical Research, Boston City Hospital, Boston University School of Medicine, Massachusetts 02118, USA.
S Chetham
S Keates
E F Bostwick
A M Roush
I Castagliuolo
J T LaMont
C Pothoulakis
Boston University · US

Funding

INTESTINAL MECHANISMS OF C DIFFICILE TOXINSR37DK034583 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LAMONT, JOHN THOMAS · 1997 to 2006
$2.8M
PURIFICATION AND MECHANISM OF C. DIFFICILE TOXINR01DK034583 · NIDDK · BOSTON UNIVERSITY MEDICAL CENTER HOSP · PI LAMONT, JOHN THOMAS · 1986 to 1996
–
NIDDK NIH HHS DK-34583
6 · The paper itself

Abstract

To be therapeutically active, oral hyperimmune bovine immunoglobulin concentrate (BIC) must survive its passage through the intestinal tract. This led us to study the gastrointestinal stability of orally administered BIC directed against Clostridium difficile toxins (BIC-C. difficile). BIC-C. difficile was stable at neutral pH in vitro but was degraded at low pH, particularly in the presence of pepsin. Healthy volunteers (n = 6) took BIC-C. difficile (45 or 8 g) as a single oral dose. Total bovine immunoglobulin G (IgG) and specific anti-C. difficile IgG were measured in the stool. BIC was given under the following conditions: in the fasting state, in the fed state, with antacid, during omeprazole therapy, or in enteric capsules (released at pH > 6). The mean fecal bovine IgG content of 3-day stool collections was similar in the fasting (536 mg; 3.8% of the ingested dose of BIC), fed (221 mg; 1.6%), and antacid (381 mg; 2.7%) groups. Omeprazole therapy was associated with increased fecal bovine IgG levels (1253 mg; 8.8%), but this difference did not reach statistical significance (P = 0.07). Administration of 8 g of BIC-C. difficile in enteric capsules resulted in substantially higher fecal bovine IgG levels (1,124 mg; 32.7% of the oral dose) than those obtained after administration of nonencapsulated BIC (22 MG; 0.6%; P = 0.004). An inverse relationship was noted between intestinal transit time and fecal bovine IgG content (R = 0.83; P = 0.04 [data from omeprazole group]). Filtrates of stool samples collected after oral administration of BIC-C. difficile neutralized the cytotoxicity of C. difficile toxins A and B, whereas control stool filtrates did not. Bovine colostral IgG undergoes partial degradation in the intestinal tract. Exposure to acidic gastric secretions and prolonged colonic transit may both contribute to IgG degradation. Nonetheless, humans taking BIC-C. difficile orally have neutralizing antitoxin activity in their stool.

Indexed as

Gastrointestinal TransitAdministration, OralAdolescentAdultAgedAnimalsAntitoxinsBacterial ToxinsCattleClostridioides difficileCross-Over StudiesFecesFemaleGastric AcidHumansHydrogen-Ion ConcentrationAntitoxinsBacterial ToxinsImmunoglobulin GPepsin ATablets, Enteric-Coated

Identifiers

PMID9021173
PMCPMC163695
OpenAlexW2160637382

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.